Sort   by:  
 Page size 
UnknownAbiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
Not available
S-EPMC6118405 | biostudies-literature
UnknownTargeted androgen pathway suppression in localized prostate cancer: a pilot study.
Not available
S-EPMC3887479 | biostudies-literature
UnknownSLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Not available
S-EPMC3138634 | biostudies-literature
UnknownSystemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.
Not available
S-EPMC4876355 | biostudies-literature
UnknownDouble-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Not available
S-EPMC4104290 | biostudies-literature
UnknownIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Not available
S-EPMC4226804 | biostudies-literature
UnknownTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Not available
S-EPMC4872347 | biostudies-literature
Sort   by:  
 Page size